INTERFERONE E VINBLASTINA NELLE METASTASI PRESUMIBILMENTE OPERABILI DA CARCINOMA RENALE

Translated title of the contribution: Interferon and vinblastine in resectable renal cell cancer metastases

G. Pizzocaro, L. Piva, M. Faustini, B. Mangiarotti, N. Nicolai, R. Salvioni, A. Milani, F. Zanoni

Research output: Contribution to journalArticlepeer-review

Abstract

From January 1987 to December 1990, 14 consecutive patients with resectable metastases from renal cell carcinoma, underwent 3 cycles of preoperative α-2a Interferon (INF), 18 MUI s.c. 3 times a week, and Vinblastine (VLB), 0.15 mg/kg on day 1, every 21 days. Out of the 13 patients who completed the treatment, 4 (30.7%) achieved a clinical response (1 CR and 3 PR). Nine (69.3%) patients were submitted to surgery: all, including the CRer, had residual cancer and only 4 were radically resected. The latter were furtherly submitted to 3 INF and VLB cycles: 2 relapsed after 7 and respectively 30 months, whilst 2 (15.4%) are alive disease-free at 12 and 52 months respectively.

Translated title of the contributionInterferon and vinblastine in resectable renal cell cancer metastases
Original languageItalian
Pages (from-to)177-180
Number of pages4
JournalArchivio italiano di urologia, nefrologia, andrologia : organo ufficiale dell"Associazione per la ricerca in urologia = Urological, nephrological, and andrological sciences
Volume65
Issue number2
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Interferon and vinblastine in resectable renal cell cancer metastases'. Together they form a unique fingerprint.

Cite this